Is PTC THERAPEUTICS, INC. (PTCT) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 52.1% / 30% | 37.4% / 30% | 3.5% / 30% | 0.44% / 5% | ✗ NOT HALAL |
| DJIM | 52.1% / 33% | 37.4% / 33% | 3.5% / 33% | 0.44% / 5% | ✗ NOT HALAL |
| MSCI | 93.4% / 33% | 67.1% / 33% | 6.3% / 33% | 0.44% / 5% | ✗ NOT HALAL |
| S&P | 52.1% / 33% | 37.4% / 33% | 3.5% / 33% | 0.44% / 5% | ✗ NOT HALAL |
| FTSE | 93.4% / 33% | 67.1% / 33% | 6.3% / 50% | 0.44% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 71.0% | |
| Operating Margin | -49.6% | |
| Net Margin | 39.4% | |
| Return on Assets (ROA) | 23.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $711M |
| Free Cash Flow | $411M |
| Total Debt | $2.7B |
| Current Ratio | 2.3 |
| Total Assets | $2.9B |
Price & Trading
| Last Close | $67.00 |
| 50-Day MA | $69.87 |
| 200-Day MA | $64.12 |
| Avg Volume | 1.2M |
| Beta | 0.6 |
|
52-Week Range
$35.95
| |
About PTC THERAPEUTICS, INC. (PTCT)
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is PTC THERAPEUTICS, INC. (PTCT) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), PTC THERAPEUTICS, INC. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is PTC THERAPEUTICS, INC.'s debt ratio?
PTC THERAPEUTICS, INC.'s debt ratio is 52.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 93.4%.
What are PTC THERAPEUTICS, INC.'s key financial metrics?
PTC THERAPEUTICS, INC. has a market capitalization of $5.5B, trailing P/E ratio of 7.7, and revenue of $1.7B. The company maintains a gross margin of 71.0% and a net margin of 39.4%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.